Hedera Dx has closed a €15 million Series A round led by Vsquared Ventures, with participation from new investor Tesi and existing backers Helsana HealthInvest, Eyrir Venture Management, Inventure, and Top Harvest. The company develops blood-based liquid biopsy tests that allow hospital labs outside the US to perform molecular cancer diagnostics more efficiently and affordably. The funding will support the company’s commercial growth across Europe and the further development of its platform, which combines molecular profiling with real-world clinical data to inform cancer treatment decisions. Hedera Dx’s solutions aim to improve access to precision oncology diagnostics in healthcare systems requiring local testing.
Outside the U.S., where centralized testing dominates, healthcare systems require diagnostics to be performed within hospital labs. Founded in 2021, Hedera Dx has developed blood-based cancer testing solutions, known as liquid biopsies, to allow for cost efficient and easy to adopt in-house testing of cancer patients. The solution combines affordability with unprecedented quality and is already deployed across 11 European countries.
With strong Nordic roots—co-founder and CEO Tommi Lehtonen brings extensive experience from Finland’s genetics sector—the company reflects the Nordic commitment to innovation, patient-centric healthcare, and high standards in medical technology. Hedera Dx’s team combines expertise from leading institutions and companies across the Nordics and Europe, aiming to make precision oncology accessible to patients worldwide through scalable, locally deployable diagnostics solutions.
The company is now quickly becoming Europe’s leading platform for precision oncology. In addition to advanced molecular profiling of cancer patients that provides physicians with insights for treatment decisions, the AI-native platform also uncovers patient-centric insights from real-world data to support the development of next generation oncology treatments.
“At Hedera, we are building the infrastructure to make precision cancer care accessible to every patient and clinician — globally,” said Tommi Lehtonen, CEO and co-founder of Hedera Dx. “While there is a large number of personalized cancer treatments on the market, a very large part of patients still can’t access them. Our solutions empower hospital labs to perform sophisticated molecular diagnostics locally and cost efficiently.”
Dr. Lise Rechsteiner, General Partner at Vsquared Ventures, said:
“Hedera Dx is addressing a critical gap in global oncology care. Hedera’s approach tackles the specific challenges of hospital in-house testing and results in more patients getting tested and more patients having access to targeted therapies. Hedera Dx’s combination of diagnostics and powerful real-world data capabilities positions them to become the definitive leader in precision oncology within healthcare systems outside the US.”
The Series A funding will support continued commercial expansion and further development of the company’s real-world data infrastructure, addressing the vast global oncology market.
“We’re not only improving access to advanced cancer care for patients — we are creating an entirely new platform for real-world insights, driving access to life-saving precision oncology treatments and fueling the next wave of innovative cancer therapies” said Dr. Christian Meisel, CMO and co-founder of Hedera Dx.
Click to read more funding news.
Read the orginal article: https://arcticstartup.com/hedera-dx-raises-e15-million-series-a/
